Who Paid My Doc
Pegcetacoplan Long Term Safety and Efficacy Extension Study
Research payments
$192,384
Through program year 2024, $192,384 in research payments was reported against Pegcetacoplan Long Term Safety and Efficacy Extension Study, across 25 payments, paid by Apellis Pharmaceuticals, Inc..
- Paid by
- Apellis Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $5,895 | 2 |
| 2023 | Research | $186,489 | 23 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Caroline Piatek Los Angeles, CA Named on 5 payments
- Brian Mulherin Indianapolis, IN Named on 5 payments
- Eloy Roman Miami Lakes, FL Named on 4 payments
- Clyde Jones Memphis, TN Named on 3 payments
- Olga Frankfurt Chicago, IL Named on 3 payments
- Marwan Kaskas Shreveport, LA Named on 1 payment
- Miten Patel Jacksonville, FL Named on 1 payment
- Jaroslaw MacIejewski Cleveland, OH Named on 1 payment
- Sonia Okuyama Sasaki Denver, CO Named on 1 payment
- Saeed Kronfli Takoma Park, MD Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.